GM3 Synthase Deficiency

GM3 synthase deficiency presents in infancy with refractory seizures, severe neurodevelopmental impairment, and distinctive skin pigmentation changes.

Overview

GM3 synthase deficiency is a rare genetic disorder marked by recurrent seizures (epilepsy) and profound disruption of brain development. Affected infants become irritable within the first weeks of life, develop feeding difficulties and vomiting, and fail to gain weight at the expected rate. Seizures typically begin within the first year and worsen over time, often resisting standard antiseizure medications.

Neurodevelopmental outcomes are severe: most children have profound intellectual disability and do not acquire milestones such as reaching, speaking, sitting without support, or walking. Some exhibit involuntary twisting or jerking movements of the arms (choreoathetoid). Vision and hearing, which are usually intact at birth, deteriorate as the disease progresses. The life expectancy of individuals with this condition is currently unknown.

Skin pigmentation abnormalities—dark freckle‑like spots and lighter patches on the arms, legs, and face—appear in childhood. While asymptomatic, these changes can aid diagnosis when accompanied by seizures and developmental delay.

Symptoms

• Generalized tonic‑clonic (grand‑mal) seizures causing muscle rigidity, convulsions, and loss of consciousness.
• Nonconvulsive status epilepticus (prolonged seizure activity without obvious convulsions).
• Refractory epilepsy resistant to antiseizure medications.
• Severe intellectual disability and failure to achieve developmental milestones.
• Choreoathetoid movements of the arms.
• Progressive vision and hearing impairment.
• Cutaneous dyspigmentation: dark freckle‑like spots and lighter patches on limbs and face.

Causes & Risk Factors

Mutations in the ST3GAL5 gene cause GM3 synthase deficiency. The gene encodes the enzyme GM3 synthase, which catalyzes the first step in the synthesis of gangliosides—molecules abundant in the nervous system and important for normal brain development and function. Loss‑of‑function mutations prevent production of functional GM3 synthase, halting normal ganglioside synthesis. The precise mechanisms linking enzyme loss to seizures, neurodevelopmental deficits, and skin pigmentation changes remain under investigation.

Frequency

Approximately 50 cases have been reported, predominantly from Old Order Amish communities, indicating that the condition is extremely rare.

Diagnosis

Diagnosis relies on a combination of clinical features (early‑onset refractory seizures, severe developmental delay, characteristic skin changes) and confirmatory genetic testing identifying biallelic pathogenic variants in ST3GAL5. Genetic testing resources include the Genetic Testing Registry.

Treatment & Management

Seizures associated with GM3 synthase deficiency are typically refractory to conventional antiseizure medications, and no disease‑modifying therapy is currently available. Management focuses on supportive care, seizure control attempts with multiple agents, and multidisciplinary support for developmental, visual, auditory, and dermatologic needs.

Inheritance

The disorder follows an autosomal recessive inheritance pattern. Both copies of the ST3GAL5 gene must carry pathogenic mutations for the disease to manifest. Parents of an affected individual are obligate carriers, each possessing one mutated copy but usually showing no symptoms.

Other Names for This Condition

• Amish infantile epilepsy syndrome
• Epilepsy syndrome, infantile‑onset symptomatic
• Ganglioside GM3 synthase deficiency
• Infantile‑onset symptomatic epilepsy syndrome

Additional Information & Resources

Genetic Testing Information

• Genetic Testing Registry: GM3 synthase deficiency

Genetic and Rare Diseases Information Center

• GM3 synthase deficiency

Patient Support and Advocacy Resources

• National Organization for Rare Disorders (NORD)

Clinical Trials

• ClinicalTrials.gov

Catalog of Genes and Diseases from OMIM

• SALT AND PEPPER DEVELOPMENTAL REGRESSION SYNDROME; SPDRS

Scientific Articles on PubMed

• Farukhi F, Dakkouri C, Wang H, Wiztnitzer M, Traboulsi EI. Etiology of vision loss in ganglioside GM3 synthase deficiency. Ophthalmic Genet. 2006 Sep;27(3):89-91. doi: 10.1080/13816810600862626.
• Fragaki K, Ait‑El‑Mkadem S, Chaussenot A, et al. Refractory epilepsy and mitochondrial dysfunction due to GM3 synthase deficiency. Eur J Hum Genet. 2013 May;21(5):528‑34. doi: 10.1038/ejhg.2012.202.
• Simpson MA, Cross H, Proukakis C, et al. Infantile‑onset symptomatic epilepsy syndrome caused by a homozygous loss‑of‑function mutation of GM3 synthase. Nat Genet. 2004 Nov;36(11):1225‑9. doi: 10.1038/ng1460.
• Wang H, Bright A, Xin B, Bockoven JR, Paller AS. Cutaneous dyspigmentation in patients with ganglioside GM3 synthase deficiency. Am J Med Genet A. 2013 Apr;161A(4):875‑9. doi: 10.1002/ajmg.a.35826.

Medical Encyclopedia Topics

• Bilateral tonic‑clonic seizure
• Epilepsy
• Genetics

Understanding Genetics

• What is the prognosis of a genetic condition?
• How can gene variants affect health and development?
• What does it mean if a disorder seems to run in my family?
• What are the different ways a genetic condition can be inherited?
• How are genetic conditions treated or managed?